Printer Friendly

KAISER PERMANENTE: NEW INFANT VACCINE DRAMATICALLY REDUCES THREAT OF BACTERIAL MENINGITIS AND OTHER POTENTIALLY LETHAL DISEASES

 /ADVANCE/ OAKLAND, Calif., May 4 /PRNewswire/ -- Kaiser Permanente researchers announced today that, during the calendar year 1992, use of a vaccine to immunize infants against invasive Hib disease (bacterial meningitis and several other potentially lethal childhood diseases), reduced the disease incidence in children under 18 months of age by 97 percent compared to the years 1984-1987.
 "The vaccine, HbOC (oligosaccharide conjugate Haemophilus influenza type b), is proving so effective that a number of potentially lethal illnesses are being virtually eliminated as a threat," said Henry Shinefield, M.D., a principal investigator and co-director of the Kaiser Permanente Pediatric Vaccine Study Center in Oakland. Invasive Hib disease includes bacterial meningitis, bacteremia, pneumonia and sepsis. Bacterial meningitis is a potentially deadly infection of the lining of the brain and spinal cord. Nationwide, the disease strikes 12,000-15,000 young children each year.
 Large California Study Population
 Since 1988, approximately 150,000 infants in Kaiser Permanente's Northern California population have been immunized with the vaccine, which is licensed under the name HibTITER(R) by Lederle-Praxis Biologicals. HibTITER was licensed by the FDA earlier this year. Results of the study were announced at the combined annual meeting of The Society for Pediatric Research, The American Pediatric Society and the Ambulatory Pediatric Association in Washington, D.C.
 As of December 1992, infants vaccinated in the Kaiser Permanente study have been followed up to age four years, ten months. Six cases of invasive Hib disease have been identified in vaccinated children. Of these, five occurred in children who had received only one dose of vaccine in infancy and one case of Hib meningitis occurred in a 3-1/2-year-old child who had received doses of HbOC at two, four and six months of age but no further doses of any Hib vaccines. Overall during 1992, only one case of invasive Hib disease (an unvaccinated child) was observed in children less than 18 months of age within the Kaiser Permanente population. To date, no increases in non-type b disease has been detected.
 The study's principal co-investigators are Shinefield and Steven Black, M.D., who head the Kaiser Permanente Pediatric Vaccine Study Center. Preliminary results of the Kaiser Permanente study were published in the August 1992 issue of The Pediatric Infectious Disease Journal. Last year the Kaiser Permanente Pediatric Vaccine Study Center received a $4.5-million grant from the Centers for Disease Control to establish a database to track the immunization patterns of some 245,000 children.
 Kaiser Permanente, the nation's largest independent prepaid group practice health maintenance organization (HMO), provides comprehensive medical and hospital services to more than 6.6 million members in 16 states and the District of Columbia.
 -0- 5/4/93/1000
 /CONTACT: Steven Black, M.D., 510-596-6574, or Henry Shinefield, M.D., 415-202-3597, or Beverly Hayon, 510-987-3290, all of Kaiser Permanente; or Gary Summers of Lewis and Summers, 510-284-7004, for Kaiser Permanente/


CO: Kaiser Permanente ST: California IN: MTC HEA SU: PDT

ML-GT -- SF002 -- 3121 04/30/93 10:30 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 30, 1993
Words:497
Previous Article:JLG INDUSTRIES ANNOUNCES REMOVAL OF CHAIRMAN OF THE BOARD, AND FORMATION OF EXECUTIVE COMMITTEE
Next Article:SOUTH CAROLINA ELECTRIC & GAS COMPANY ANNOUNCES FIRST MORTGAGE BOND REDEMPTIONS
Topics:


Related Articles
KAISER PERMANENTE: NEW INFANT VACCINE WIPES OUT SOME KILLER DISEASES
MAJOR CAUSE OF BACTERIAL MENINGITIS ERADICATED IN KAISER PERMANENTE POPULATION
KAISER PERMANENTE: STUDY ANSWERS LONG-STANDING MEDICAL QUESTION
VACCINE EFFECTIVE AGAINST MENINGITIS AND BACTEREMIA.
American Home Products Corporation Announces - FDA Designates Wyeth Lederle Vaccines' Pneumococcal Conjugate Vaccine for Fast-Track Development.
American Home Products Corporation's Wyeth Lederle Vaccines Seeks FDA License For Vaccine to Help Prevent Pneumococcal Disease in Children.
Investigational Vaccine May Reduce Pneumonia in Children.
Study: Antibiotic Treatment During Labor Does Not Delay Symptoms Of Group B Strep in Newborns.
Kaiser Permanente Research: New Nasal Flu Vaccine to be Studied In 15,000 Children.
Kaiser Permanente Research Reaffirms Safety of Flu Vaccine for Young Children.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters